In the treatment of prostate cancer resistance, inhibition of AKT/mTOR will feedback enhance MAPK signaling, and conversely, MEK inhibitors will relieve S6K’s inhibition of IRS1, activate the PI3K-AKT pathway, and lead to compensatory escape. Here, PIK3CA is linked to prostate carcinoma.